



Making Science work for you...

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

9M FY 2007

Net Sales up
25%

EBIDTA up
78%

PAT up
101%

Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2006

(Rs. in Million)

(Rs. in Million)

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended December 31 (Unaudited)		Nine Months Ended December 31 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended December 31 (Unaudited)		Nine Months Ended December 31 (Unaudited)		Year Ended March 31 (Audited)
2006	2005	2006	2005	2006		2006	2005	2006	2005	2006
2937	2805	8274	7765	10292	Domestic sales & services	2932	2805	8270	7765	10292
2114	1718	6183	3890	5887	International sales	1554	1291	4524	3293	4757
5051	4523	14457	11655	16179	Gross sales	4486	4096	12794	11058	15049
(358)	(303)	(993)	(891)	(1189)	Less: Excise Duty on Sales	(358)	(303)	(993)	(891)	(1189)
4693	4220	13464	10764	14990	Net sales	4128	3793	11801	10167	13860
168	36	403	101	197	Other income	28	35	246	89	177
4861	4256	13867	10865	15187	Total income	4156	3828	12047	10256	14037
3795	3574	11066	9287	12820	Total expenditure	3161	3145	9355	8646	11657
(163)	(44)	(252)	(134)	(186)	a) (Increase)/Decrease in stock of manufactured goods	(135)	(35)	(269)	(24)	(111)
119	276	306	404	463	b) Cost of trading goods sold	112	255	263	371	403
2245	1838	6050	5261	7142	c) Raw & process materials consumed	2127	1797	5818	5176	7013
284	196	795	538	760	d) Stores, spares, chemicals, catalyst & packing material consumed	255	182	694	507	706
319	299	962	897	1162	e) Manufacturing expenses	319	299	962	897	1162
144	121	381	321	435	- Cost of power & fuel	136	122	367	310	418
581	443	1597	879	1360	- Other manufacturing expenses	262	220	704	557	771
266	445	1227	1121	1684	f) Staff cost	85	305	816	852	1295
1066	682	2801	1578	2367	Operating profit before interest and depreciation	995	683	2692	1610	2380
49	54	141	143	173	Interest (Net)	30	42	105	128	147
1017	628	2660	1435	2194	Operating profit before depreciation	965	641	2587	1482	2233
158	129	457	358	513	Depreciation	131	111	384	314	442
859	499	2203	1077	1681	Profit before tax	834	530	2203	1168	1791
236	121	590	256	392	Provision for tax (Including Deferred Tax & Fringe Benefit Tax and net of reversals/credit)	231	121	584	254	403
623	378	1613	821	1289	Net profit after tax	603	409	1619	914	1388
(14)	12	(29)	6	(8)	Minority Interest	-	-	-	-	-
637	366	1642	815	1297	Net profit after Minority Interest	603	409	1619	914	1388
143.4	140.3	143.4	140.3	142.5	Paid-up share capital (Face value of the share is Re. 1)	143.4	140.3	143.4	140.3	142.5
				8115	Reserves (excluding revaluation reserve)					8102
4.45	2.70	11.48	6.03	9.48	Earnings per share (Not annualized) Basic (Rs.)	4.21	3.02	11.32	6.76	10.15
3.59	2.47	9.44	5.45	8.57	Diluted (Rs.)	3.39	2.76	9.31	6.11	9.17
69064310	66122525	69064310	66122525	68452650	Aggregate of non-promoter shareholding	69064310	66122525	69064310	66122525	68452650
48.15	47.14	48.15	47.14	48.06	- Number of shares (Re. 1 each)	48.15	47.14	48.15	47.14	48.06
					- Percentage of shareholding					

Notes:

- The above un-audited results which are subjected to limited review by the auditors of the company, were reviewed by the Audit Committee and have been taken on record by Board at its meeting held on 16th January, 2007.
- During the Quarter, the Company through its wholly owned subsidiary Jubilant Pharma Pte Limited, Singapore invested US\$ 1.59 million in Trigen Laboratories Inc. as per the Share Purchase Agreement and increased its equity interest to 75.0%.
- The Company issued, Foreign Currency Convertible Bonds (FCCBs) aggregating to US\$ 310 million, out of which US\$ 33.10 million have been converted into equity shares. The Company has utilized part of the FCCBs proceeds towards capital expenditure, acquisition of overseas subsidiaries, and balance of US\$ 190 million kept in cash account.

Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)										
CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended December 31 (Unaudited)		Nine Months Ended December 31 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended December 31 (Unaudited)		Nine Months Ended December 31 (Unaudited)		Year Ended March 31 (Audited)
2006	2005	2006	2005	2006		2006	2005	2006	2005	2006
					Segment revenue					
2428	1899	7104	4778	7019	a. Pharmaceuticals & Life Science Products	1863	1472	5439	4181	5885
2081	2113	5705	5294	7080	b. Industrial Products	2081	2113	5705	5294	7080
560	530	1708	1631	2148	c. Performance Polymers	560	530	1710	1631	2152
5069	4542	14517	11703	16247	Gross sales	4504	4115	12854	11106	15117
18	19	60	48	68	Less : Inter segment revenue	18	19	60	48	68
358	303	993	891	1189	Less : Excise Duty on sales	358	303	993	891	1189
4693	4220	13464	10764	14990	Net sales	4128	3793	11801	10167	13860
2348	1840	6880	4593	6773	a. Pharmaceuticals & Life Science Products	1783	1413	5215	3996	5639
1852	1915	5077	4742	6333	b. Industrial Products	1852	1915	5077	4742	6333
493	465	1507	1429	1884	c. Performance Polymers	493	465	1509	1429	1888
4693	4220	13464	10764	14990	Total	4128	3793	11801	10167	13860
					Segment results (profit+)/loss(-) before tax and interest from each segment					
378	342	1324	842	1261	a. Pharmaceuticals & Life Science Products	434	361	1388	918	1345
260	219	663	404	658	b. Industrial Products	263	219	666	404	658
26	23	96	66	95	c. Performance Polymers	26	23	96	66	95
664	584	2083	1312	2014	Total	723	603	2150	1388	2098
49	54	141	143	173	Less : i. Interest	30	42	105	128	147
(244)	31	(261)	92	160	ii. Other un-allocable expenditure (net of un-allocable income)	(141)	31	(158)	92	160
859	499	2203	1077	1681	Total profit before tax	834	530	2203	1168	1791
					Capital Employed (Segment assets less Segment liabilities)					
13574	10344	13574	10344	10846	a. Pharmaceuticals & Life Science Products	8603	6702	8603	6702	7180
3877	3472	3877	3472	4377	b. Industrial Products	3877	3472	3877	3472	4377
470	463	470	463	496	c. Performance Polymers	463	463	463	463	492
17921	14279	17921	14279	15719	Total Capital employed in segments	12943	10637	12943	10637	12049
8420	1314	8420	1314	951	Add: Un-allocable corporate assets less liabilities	12597	3842	12597	3842	3492
26341	15593	26341	15593	16670	Total capital employed in the Company	25540	14479	25540	14479	15541

- Other income includes interest income on unutilized proceeds of FCCBs of Rs. 11.0 million for Q3 and Rs. 189.41 million for Nine months ended 31st December, 2006 (Consolidated Rs. 129.56 million and Rs. 307.97 million respectively).
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New - 72, Disposals - 72, Closing Balance - Nil.
- Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.

For Jubilant Organosys Ltd.

Place : Noida
Dated : 16th January, 2007

Shyam S Bhartia
Chairman & Managing Director

visit us at www.jubl.com